News articles about DexCom (NASDAQ:DXCM) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. DexCom earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the medical device company an impact score of 46.0928383662633 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:

DXCM has been the topic of several recent analyst reports. Northland Securities initiated coverage on shares of DexCom in a report on Tuesday, September 26th. They issued an “outperform” rating and a $85.00 price target on the stock. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and cut their price target for the company from $93.00 to $71.00 in a report on Thursday, September 28th. Citigroup cut shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Thursday, September 28th. Jefferies Group reaffirmed a “buy” rating and issued a $91.00 price target on shares of DexCom in a report on Thursday, September 28th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $76.00 price target (down from $85.00) on shares of DexCom in a report on Thursday, September 28th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. DexCom presently has a consensus rating of “Buy” and a consensus price target of $68.50.

Shares of DexCom (NASDAQ DXCM) traded down $0.09 during trading hours on Wednesday, hitting $56.32. 1,263,170 shares of the company’s stock were exchanged, compared to its average volume of 2,120,818. The firm has a market capitalization of $4,860.00, a PE ratio of -98.81 and a beta of 0.31. DexCom has a 52 week low of $42.62 and a 52 week high of $86.32. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.11. DexCom had a negative net margin of 7.21% and a negative return on equity of 20.44%. sell-side analysts predict that DexCom will post -0.64 earnings per share for the current fiscal year.

In related news, CEO Kevin R. Sayer sold 12,000 shares of the stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $55.00, for a total value of $660,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $44.82, for a total transaction of $73,280.70. Following the completion of the sale, the executive vice president now directly owns 65,049 shares in the company, valued at approximately $2,915,496.18. The disclosure for this sale can be found here. Insiders have sold 38,140 shares of company stock worth $2,158,576 over the last three months. 1.70% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “DexCom (DXCM) Receiving Somewhat Favorable News Coverage, Analysis Shows” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with's FREE daily email newsletter.